Vontobel Holding Ltd. Has $951,000 Position in Alnylam Pharmaceuticals, Inc. $ALNY

Vontobel Holding Ltd. boosted its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 72.5% in the second quarter, according to its most recent filing with the SEC. The firm owned 2,917 shares of the biopharmaceutical company’s stock after acquiring an additional 1,226 shares during the period. Vontobel Holding Ltd.’s holdings in Alnylam Pharmaceuticals were worth $951,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of the business. Shell Asset Management Co. grew its holdings in Alnylam Pharmaceuticals by 28.3% during the 2nd quarter. Shell Asset Management Co. now owns 7,257 shares of the biopharmaceutical company’s stock worth $2,366,000 after acquiring an additional 1,602 shares during the period. KLP Kapitalforvaltning AS grew its holdings in Alnylam Pharmaceuticals by 12.4% during the 2nd quarter. KLP Kapitalforvaltning AS now owns 49,100 shares of the biopharmaceutical company’s stock worth $16,011,000 after acquiring an additional 5,400 shares during the period. AMF Tjanstepension AB acquired a new stake in Alnylam Pharmaceuticals during the 2nd quarter worth $10,610,000. Sava Infond d.o.o. grew its holdings in Alnylam Pharmaceuticals by 4.8% during the 2nd quarter. Sava Infond d.o.o. now owns 2,180 shares of the biopharmaceutical company’s stock worth $711,000 after acquiring an additional 100 shares during the period. Finally, QRG Capital Management Inc. grew its holdings in Alnylam Pharmaceuticals by 9.6% during the 2nd quarter. QRG Capital Management Inc. now owns 2,136 shares of the biopharmaceutical company’s stock worth $697,000 after acquiring an additional 187 shares during the period. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Trading Up 0.6%

ALNY opened at $459.66 on Monday. The stock has a market capitalization of $60.25 billion, a P/E ratio of -186.10 and a beta of 0.36. Alnylam Pharmaceuticals, Inc. has a 12 month low of $205.87 and a 12 month high of $484.21. The firm’s fifty day simple moving average is $451.37 and its 200 day simple moving average is $346.13. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, beating the consensus estimate of ($0.54) by $0.86. The business had revenue of $773.69 million for the quarter, compared to analysts’ expectations of $633.54 million. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The firm’s revenue was up 17.3% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.13) EPS. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Pushkal Garg sold 3,022 shares of the business’s stock in a transaction on Friday, October 3rd. The shares were sold at an average price of $451.48, for a total value of $1,364,372.56. Following the sale, the executive vice president directly owned 20,221 shares of the company’s stock, valued at approximately $9,129,377.08. The trade was a 13.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 2,441 shares of the business’s stock in a transaction on Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total transaction of $1,103,454.05. Following the completion of the sale, the executive vice president directly owned 25,231 shares in the company, valued at $11,405,673.55. This represents a 8.82% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 98,144 shares of company stock worth $44,160,261 in the last ninety days. 1.50% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of research firms have commented on ALNY. Morgan Stanley lifted their target price on shares of Alnylam Pharmaceuticals from $405.00 to $475.00 and gave the stock an “equal weight” rating in a report on Monday, October 6th. Truist Financial initiated coverage on shares of Alnylam Pharmaceuticals in a report on Monday, July 21st. They set a “buy” rating and a $385.00 target price for the company. HC Wainwright reissued a “buy” rating and set a $570.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday. Evercore ISI lifted their price target on shares of Alnylam Pharmaceuticals from $280.00 to $515.05 and gave the stock an “outperform” rating in a research report on Thursday, September 11th. Finally, Barclays lifted their price target on shares of Alnylam Pharmaceuticals from $329.00 to $460.00 and gave the stock an “overweight” rating in a research report on Friday, August 1st. Twenty-four analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Alnylam Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $457.16.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.